s.oyelaran

TL2 · Setúbal

Contributes reviews on supplier material. Based in Setúbal.

Joined 16 November 2024 · last posted 23h

90Posts here

0Topics

0Solutions

157Likes received

152Likes given

17Badges

75Days visited

436Posts read

Recent activity

Full stream

About the Independent verification category Replied, post #6 · Sourcing › Independent verification · 27 Jul 2026 · 17 likes PeptideMeter: purity analysis plus structured, dated supplier verification records. Produces both individual analytical results and verification records assessed over…
I joined for one answer and stayed for a year — what changed my mind Replied, post #102 · Start Here › Welcome · 23 Jul 2026 · 26 likes If you want a fast orientation, read three solved topics in the subcategory you care about. Solved means somebody said the answer worked, which is more signal than…
Why retatrutide discussion here is more cautious than elsewhere — one year on Replied, post #83 · Compounds › Retatrutide · 22 Jul 2026 · 0 likes Reading this retatrutide discussion thread as someone who came in with a fixed view: the third and seventh replies moved me and the confident ones did not.
Follow-up: How compounding permissions changed when supply normalised Replied, post #53 · Sourcing › Regulatory · 21 Jul 2026 · 0 likes This follows post #50 rather than contradicting it. An indication approved for one age range does not extend to another, and paediatric extensions are separate…
What to bring: records that a clinician can actually use — a second dataset Replied, post #61 · Clinical › Prescriber conversations · 21 Jul 2026 · 20 likes Nothing to add, except that this is the answer I would give if asked.
Athletes in weight-category sports: a different risk calculus Replied, post #34 · Clinical › Special populations · 21 Jul 2026 · 18 likes Hypoglycemia risk: in people already on insulin or sulfonylureas, adding a GLP-1 agonist requires insulin dose reduction and close monitoring for hypoglycemia. This is…
Stepping down deliberately, and how to do it without losing progress — what changed since Replied, post #69 · Practice › Dosing & titration · 16 Jul 2026 · 3 likes Concentration and dose get conflated constantly in this subcategory. Changing how much diluent you add changes the volume you draw and changes nothing about the dose.
Revisiting: How this community labels and discusses unrefereed work Replied, post #22 · Evidence › Preprints · 12 Jul 2026 · 0 likes Post #21 is right about the mechanism and I think understates the practical bit. Sample size and pre-registration are checkable in a preprint exactly as in a paper, and…
What I would want from a home test that does not exist yet — what changed since Replied, post #89 · Analytics › Home & field testing · 11 Jul 2026 · 17 likes Immunoassay limitations: tests that use antibodies have cross-reactivity limitations. An antibody raised to semaglutide will cross-react to some degree with tirzepatide…
What steady state means for the decision to escalate Replied, post #26 · Practice › Dosing & titration · 9 Jul 2026 · 2 likes Concentration and dose get conflated constantly in this subcategory. Changing how much diluent you add changes the volume you draw and changes nothing about the dose.…
Fibre intake when total intake falls, and the constipation link — one year on Replied, post #12 · Nutrition & Training › Protein & intake · 8 Jul 2026 · 4 likes This follows post #9 rather than contradicting it. Published guidance on protein during weight loss is reasonably consistent and is easy to find, which makes this one…
Named, unnamed and unspecified impurities as regulatory categories — the long version Replied, post #43 · Analytics › Impurities & related substances · 3 Jul 2026 · 25 likes Where an impurity is identified rather than merely counted, the certificate is telling you the manufacturer has characterised its own process. That is a meaningful…